A Phase II Study of Immunotherapies (Tiragolumab and Atezolizumab) in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Latest Information Update: 20 Dec 2024
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Tiragolumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Dec 2024 Planned initiation date changed from 19 Dec 2024 to 22 Dec 2024.
- 16 Dec 2024 Planned initiation date changed from 18 Dec 2024 to 19 Dec 2024.
- 13 Dec 2024 Planned initiation date changed from 9 Dec 2024 to 18 Dec 2024.